4//SEC Filing
Naschitz Anat 4
Accession 0000899243-19-027225
CIK 0001785173other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 7:07 PM ET
Size
17.9 KB
Accession
0000899243-19-027225
Insider Transaction Report
Form 4
89bio, Inc.ETNB
Naschitz Anat
Director10% Owner
Transactions
- Purchase
Common Stock
2019-11-11$16.00/sh+418,750$6,700,000→ 724,363 total(indirect: See footnotes) - Conversion
Common Stock
2019-11-13+1,277,858→ 2,002,221 total(indirect: See footnotes) - Conversion
Common Stock
2019-11-13+1,277,858→ 2,002,221 total(indirect: See footnotes) - Conversion
Series A Preferred Stock
2019-11-13−7,944,444→ 0 total(indirect: See footnotes)→ Common Stock (1,277,858 underlying) - Conversion
Series A Preferred Stock
2019-11-13−7,944,444→ 0 total(indirect: See footnotes)→ Common Stock (1,277,858 underlying) - Purchase
Common Stock
2019-11-11$16.00/sh+418,750$6,700,000→ 724,363 total(indirect: See footnotes)
Footnotes (5)
- [F1]On November 11, 2019, OrbiMed Private Investments VI, LP ("OPI VI") purchased 418,750 shares of the Issuer's common stock and OrbiMed Israel Partners II, L.P. ("OIP II") purchased 418,750 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering.
- [F2]The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.
- [F3]These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC ("OrbiMed GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed GP VI. By virtue of such relationships, OrbiMed GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein.
- [F4]These securities are held of record by OIP II. OrbiMed Israel GP II, L.P. ("Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("Advisors Israel II") is the general partner of Israel GP II. Advisors Israel II and Israel GP II may be deemed to have shared voting and investment power over all of the shares of common stock held by OIP II, and both Advisors Israel II and Israel GP II may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares held by OIP II. Advisors Israel II exercises this investment power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II. The Reporting Person disclaims beneficial ownership of the shares held by OIP II, except to the extent of her pecuniary interest therein, if any.
- [F5]The Reporting Person is an Employee of Advisors Israel II. Each of OrbiMed GP VI, OrbiMed Advisors, Israel GP II, Advisors Israel II, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
89bio, Inc.
CIK 0001785173
Entity typeother
Related Parties
1- filerCIK 0001792060
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 7:07 PM ET
- Size
- 17.9 KB